Ardena has announced that it has completed the divestment of its drug substance site in Södertälje, Sweden, to Nanologica AB, which will once more be called Syntagon AB and will operate as a wholly-owned subsidiary.
The Södertälje site offers CDMO services with a focus on small molecule APIs for programs from early development to clinical supply and commercial manufacturing. Prior to the sale, Ardena has invested in chromatographic purification and falling film distillation at the site.
Nanologica is a life science tools company that, among other offerings, develops silica-based products for the purification of peptide drugs. The company has a longstanding relationship with Ardena. To ease the transition of ownership to Nanologica, Ardena will continue to offer customer support and will be collaborating with Nanologica on some new customer projects.